Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
allogeneic adipose derived mesenchymal stem cell (2 trials)
autologous mononuclear stem cell (2 trials)
Multiple Sclerosis (Phase 2)
Multiple Sclerosis, Relapsing-Remitting (Phase 2)
Sclerosis (Phase 2)
Trials (2 total)
Trial APIs (2 total)